ATC

Important terms

Here are some terms associated with synovial sarcoma and TCR T-cell therapy that are mentioned on this website. You can explore these terms for more insight into this disease and treatment.

Adoptive cell therapy

A kind of immunotherapy in which T cells are given to a patient to help the body fight diseases like cancer. In cancer therapy, these T cells are usually collected from the patient's own blood or tumor tissue, engineered in a laboratory to better locate and kill the cancer cells, and then given back to the patient to help their immune system fight the cancer. Types of adoptive cell therapy include chimeric antigen receptor T-cell (CAR-T) therapy, tumor-infiltrating lymphocyte (TIL) therapy, or T-cell receptor (TCR) T-cell therapy.

Apheresis

A procedure where blood is collected from a person, then part of the blood, like white blood cells or platelets, is taken out, and the rest of the blood is returned to the person.

Authorized Treatment Center (ATC)

Specific treatment centers that have the right tools and experts to administer TECELRA.

Biomarker

A biological molecule found in a person's blood, other body fluids, or tissues. This can be a sign of a normal or abnormal body process, or a sign of a condition or disease. Biomarkers may be used to determine whether a person will respond to treatment for a condition or disease.

Cytokine release syndrome (CRS)

A condition that can occur with some immunotherapies when immune cells create a large and rapid release of cytokines, proteins that affect the immune system, into the blood. Signs and symptoms can include fever, fast or irregular heartbeat, low blood pressure, nausea/vomiting, and headache. The reaction may be serious or life-threatening.

Engineer

The process of modifying T cells to have special TCRs that are better able to target and destroy synovial sarcoma cells.

Leukapheresis

The collection of blood from a person so that white blood cells may be taken out. The remaining blood is then returned to the body.

Lymphodepletion

A short course of chemotherapy given to temporarily reduce the amount of normal white blood cells within the immune system. This is done to provide more “space” for the engineered immune cells infused during treatment.

Metastasize

When the cancer spreads from its original location to other parts of your body. The metastatic tumors formed by the cells that traveled through the blood or lymph system are the same kind of cancer as the original tumor.

Stem cell therapy

Any treatment which involves human stem cells. A common type is stem cell transplant, in which a patient receives healthy stem cells (generally blood-forming cells) to replace their cells that were affected by cancer or treatment for the cancer. These stem cells can come from the patient, a related donor, or an unrelated donor.

Synovial sarcoma

A type of cancer usually found in the tissue around the major joints in the arms and legs, though it can also form elsewhere in the body. It is a kind of soft tissue sarcoma and often occurs in younger populations.

T cell

A type of white blood cell that is part of the immune system. They help protect a person from infection and may help fight cancer by binding to and attacking certain substances or tissue.

T-cell receptor (TCR)

A group of proteins found on T cells that bind to certain proteins on other cells, including cancerous or abnormal cells. Once connected, the T cells can attack these cells to help the body fight cancer, infection, and other diseases.

T-cell therapy

A therapy that takes T cells from a person's body through leukapheresis, engineers them to better locate the targeted disease cells—like a certain kind of cancer cell—and puts them back in the person's body to help fight the disease.

Tumor

An abnormal mass of tissue, or lump, formed when cells replicate more than they should. They may be cancer (malignant tumors) or not cancer (benign tumors). If malignant, they can grow into other tissues or spread to other parts of the body (see definition for Metastasize above).

want to learn more?

Learn about cell therapy arrow icon Discover how TECELRA works arrow icon Explore more about the
synovial sarcoma journey arrow icon

INDICATION and IMPORTANT SAFETY INFORMATION

What is TECELRA?

TECELRA is a medicine, called a genetically modified autologous T cell immunotherapy, that is used to treat synovial sarcoma. It is used when other kinds of treatment do not work. TECELRA is different from other cancer medicines because it is made from your own white blood cells that are made to recognize and attack your cancer cells. Your healthcare provider will perform tests to see if TECELRA is right for you. TECELRA is approved based on patient response data. Additional data are needed to confirm the clinical benefit of TECELRA. It is not known if TECELRA is safe and effective in children.

Please see Medication Guide, including Important Warning.

IMPORTANT SAFETY INFORMATION

Important Warning: You will likely be in a hospital before and after getting TECELRA. TECELRA may cause side effects that can be severe or life-threatening. Call your healthcare provider or get emergency help right away if you get any of the following: fever (100.4°F/38°C or higher); chills/shivering; difficulty breathing; fast or irregular heartbeat; low blood pressure; fatigue; severe nausea, vomiting, or diarrhea; severe headache; or new skin rash. Tell all your healthcare providers that you were treated with TECELRA.

After getting TECELRA, you will be monitored daily at the healthcare facility for at least 7 days after the infusion. You should plan to stay close to a healthcare facility for at least 4 weeks. Do not drive, operate heavy machinery, or do other activities that could be dangerous for at least 4 weeks after you get TECELRA. Your healthcare provider will do blood tests to follow your progress. It is important that you have your blood tested. If you miss a scheduled appointment for your collection of blood, call your healthcare provider as soon as possible to reschedule.

Before you receive TECELRA, tell your healthcare provider about all the medicines and supplements you take and your medical conditions, including: seizure, stroke, confusion, or memory loss; heart, liver, or kidney problems; low blood pressure; lung or breathing problems; recent or active infection; past infections that can be reactivated following treatment with TECELRA; low blood counts; pregnancy, you think you may be pregnant, or plan to become pregnant; breastfeeding; or taking a blood thinner.

The most common side effects of TECELRA include nausea, vomiting, fatigue, infection, constipation, fever (100.4°F/38°C or higher), abdominal pain, difficulty breathing, decreased appetite, diarrhea, low blood pressure, back pain, fast heart rate, chest pain, general body swelling, low white blood cells, low red blood cells, and low platelets.

You are encouraged to report side effects to the FDA at (800) FDA‑1088 or www.fda.gov/medwatch or to Adaptimmune at 1‑855‑24MYADAP (1-855‑246‑9232).

Please see Medication Guide, including Important Warning.

INDICATION and IMPORTANT SAFETY INFORMATION

What is TECELRA?

TECELRA is a medicine, called a genetically modified autologous T cell immunotherapy, that is used to treat synovial sarcoma. It is used when other kinds of treatment do not work. TECELRA is different from other cancer medicines because it is made from your own white blood cells that are made to recognize and attack your cancer cells. Your healthcare provider will perform tests to see if TECELRA is right for you. TECELRA is approved based on patient response data. Additional data are needed to confirm the clinical benefit of TECELRA. It is not known if TECELRA is safe and effective in children.

Please see Medication Guide, including Important Warning.

IMPORTANT SAFETY INFORMATION

Important Warning: You will likely be in a hospital before and after getting TECELRA. TECELRA may cause side effects that can be severe or life-threatening. Call your healthcare provider or get emergency help right away if you get any of the following: fever (100.4°F/38°C or higher); chills/shivering; difficulty breathing; fast or irregular heartbeat; low blood pressure; fatigue; severe nausea, vomiting, or diarrhea; severe headache; or new skin rash. Tell all your healthcare providers that you were treated with TECELRA.

After getting TECELRA, you will be monitored daily at the healthcare facility for at least 7 days after the infusion. You should plan to stay close to a healthcare facility for at least 4 weeks. Do not drive, operate heavy machinery, or do other activities that could be dangerous for at least 4 weeks after you get TECELRA. Your healthcare provider will do blood tests to follow your progress. It is important that you have your blood tested. If you miss a scheduled appointment for your collection of blood, call your healthcare provider as soon as possible to reschedule.

Before you receive TECELRA, tell your healthcare provider about all the medicines and supplements you take and your medical conditions, including: seizure, stroke, confusion, or memory loss; heart, liver, or kidney problems; low blood pressure; lung or breathing problems; recent or active infection; past infections that can be reactivated following treatment with TECELRA; low blood counts; pregnancy, you think you may be pregnant, or plan to become pregnant; breastfeeding; or taking a blood thinner.

The most common side effects of TECELRA include nausea, vomiting, fatigue, infection, constipation, fever (100.4°F/38°C or higher), abdominal pain, difficulty breathing, decreased appetite, diarrhea, low blood pressure, back pain, fast heart rate, chest pain, general body swelling, low white blood cells, low red blood cells, and low platelets.

You are encouraged to report side effects to the FDA at (800) FDA‑1088 or www.fda.gov/medwatch or to Adaptimmune at 1‑855‑24MYADAP (1-855‑246‑9232).

Please see Medication Guide, including Important Warning.

You are now leaving this site

This link will take you to a third-party site that is not owned by Adaptimmune. Click “OK” if you would like to proceed or click “Cancel” to stay on this site.

OK
Cancel